Description


This completely free, year-long series provides live access to dozens of expert faculty from the Massachusetts General Hospital Department of Psychiatry. In each of the 20 one-hour sessions, broadcasted in Boston, MA, you have the opportunity to not only hear the latest evidence-based research and data, but also ask clinical questions that help you translate that research into your daily clinical practice and care for patients.

Topics in this interactive series focus on unmet psychopharmalogical treatment needs for patients with psychosis, depression, autism, anxiety, substance abuse and more. Faculty include some of the world’s leading clinician-researchers in their respective fields, and they discuss effective evidenced-based psychopharmacological strategies, management of somatic symptoms and medication side effects, and best-practice psychopharmacological approaches to psychiatric disorders in special populations.

  • Every session includes live Q&A with faculty – yet each session is also available on-demand, so you can view the entire series or a single session at any time during the year.
  • Use these sessions to educate your entire staff in a community hospital or practice, or simply stay up-to-date as an individual clinician.
  • Earn CME/CE credits for physicians, psychologists, nurses and social workers.

Overall Learning Objectives

At the end of this educational activity, participants should be able to:
  • Identify evidenced based psychopharmacological strategies to effectively manage difficult to treat psychiatric disorders.
  • Recognize and manage somatic symptoms and those associated with medication side effects.
  • Review novel and best practice psychopharmacological approaches to psychiatric disorders in special populations.
  • Formulate appropriate pharmacologic treatment strategies for patients with multiple psychiatric diagnoses.

Target Audience

Psychiatrists, primary care/family physicians, nurses, allied healthcare professionals

Schedule

All broadcasts promptly start at 11 am EST

Launch date

Topic

Speaker

10/3/2012

 

Managing Medication Side Effects in Schizophrenia

David Henderson, MD

10/17/2012

Challenges and Opportunities in Treating Mood Disorders in Women

Lee S. Cohen, MD

10/31/2012

Novel Approaches to the Treatment of Bipolar Depression

 Andrew Nierenberg, MD

11/14/2012

Treating Nicotine Dependence in Co-occurring Psychiatric Disorders

A. Eden Evins, MD, MPH

11/28/2012 

Difficult to Treat Depression in Medical Illness

Gregory Fricchione, MD

12/12/2012

Diagnosis and Treatment of ADHD Throughout the Lifespan

Joseph Biederman, MD

1/2/2013

Treatment-Resistant Depression

George Papakostas, MD

1/16/2013

Challenges in the Management of Acute and Transient Psychotic Disorders

Oliver Freudenreich, MD

1/30/2013

Psychobiology of PTSD

Roger Pitman, MD

2/6/2013

Evaluation and Treatment of Chronic Pain: A Focus on Migraine and Psychiatric Comorbidities

Mia Minen, MD

2/20/2013

Substance Use Disorders in Youth

John Kelly, PhD

3/6/2013

Managing Treatment Resistant Anxiety Disorders

Naomi Simon, MD, MSc

3/20/2013

Pharmacotherapy of Opioid Dependence

John Renner, MD

4/3/2013

Anxious Depression: A Difficult to Treat Clinical Entity

Maurizio Fava, MD

4/17/2013

Adjunctive Treatment for Schizophrenia

Joshua Roffman, MD

5/1/2013

From the Lab to the Clinic: Translational Advances for Depression and Anxiety Disorders

Diego Pizzagalli, MD

5/15/2013

Treatment of Patients with Co-occuring Substance Dependence and Bipolar Disorder

Roger Weiss, MD

5/29/2013

How Do We Recognize and Treat Autism

Christopher McDougle, MD

6/12/2013

Bipolar Disorder in Children and Adolescents: The Controversy

Janet Wozniak, MD

6/26/2013

Chronic Pain in Depression

Karsten Kueppenbender, MD, CPG

CME Information

Sponsored by:

Partners HealthCare
Partners HealthCare

 

Live Event Details

Dates: Every other Wednesday at 11:00am ET, beginning on October 3, 2012

To receive credit for each of the 19 one-hour sessions, you must view the presentation and complete the post-test and activity evaluation. Upon completion, you will be able to receive one credit for each individual session. 

 

Accreditation
Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Partners HealthCare System designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

On Demand Event Details

Release Date: October 3, 2012 

 

Expiration Date: June 26, 2014

Accreditation 
Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Partners HealthCare System designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists: The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meeting the criteria for 1 Continuing Education (CE) credit per presentation for psychologists.

Social Workers: This program has been approved for 1 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 60148.


Policy on Faculty and Provider Disclosure
It is the policy of Partners HealthCare System that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. Partners HealthCare System has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.


Planner Disclosures

The following planners of this activity have indicated that neither they nor their spouse/partner have a relevant financial relationship to disclose:

John A. Fromson, MD: Planner, reviewer

Tristan Gorrindo, MD: Planner

Anan Nathif, EdM: Planner

 

The following planners of this activity have indicated that either they or their spouse/partner have a relevant financial relationship to disclose:

Jerrold F. Rosenbaum, MD: Planner

Senior Advisory Board:

Medavante

Equity Holdings:

Medavante and Supernus.

 

Maurizio Fava, MD: Planner

Research Support:
Abbot Laboratories; Alkermes, Inc.;Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clinical Trials Solutions, LLC; Clintara, LLC; Covance; Covidien; Eli Lilly and Company; ElMindA, Ltd.; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmavite® LLC; Photothera; Roche Pharmaceuticals; RCT Logic, LLC; Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories
Advisory/Consulting:
Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Clinical Trials Solutions, LLC; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; RCT Logic, LLC; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.
Speaking/Publishing:
Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst LaboratoriesEquity Holdings: Compellis
Royalty/patent, other income:
Patent for Sequential Parallel Comparison Design (SPCD) and patent application for a combination of azapirones and bupropion in Major Depressive Disorder (MDD); for research and licensing of SPCD with RCT Logic.Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd.


Supporters:

This program has received support in the form of educational grants from the following companies:

  • Janssen Scientific Affairs, LLC
  • Lilly USA, LLC
  • Sunovian Pharmaceuticals, Inc.
  • Takeda Pharmaceutical International, Inc. and Lundbeck

Hardware/Software Specifications: 

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh:
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit


Privacy Policy:
 
Please click here to review our privacy policy.

Supporters

This program has received support in the form of educational grants from the following companies: